Joint process development between Sartorius Stedim Biotech and greenovation Biotech GmbH
Sartorius Stedim Biotech GmbH and greenovation Biotech GmbH agreed to collaborate on the project of processscale implementation of the innovative, plant-based bryotechnology developed by greenovation.
In the past years, greenovation Biotech and Sartorius Stedim Biotech have been working together successfully on developing fermentation processes in the field of bryotechnology. Now, greenovation Biotech GmbH is planning the process-scale application of its proprietary technology for producing complex proteins from moss cells. The next step in this collaboration is that Sartorius Stedim Biotech will deliver to greenovation the first GMP-compliant photobioreactor for bryotechnological applications as early as within the next few months.
Unlike other established production technologies that utilize mammalian cells, bryotechnology makes it possible to fully simplify the process engineering involved with drug manufacturing, according to the company. Since moss cells are relatively undemanding, they can be cultivated using relatively simple culture medium compositions, which significantly reduces the complexity involved in controlling the process. Moreover, the use of bryotechnology will result in a significant reduction in investment costs and ultimately in more affordable biopharmaceutical medicines.
The aim of the cooperative agreement between Sartorius Stedim Biotech and greenovation Biotech is to further promote the development of this promising and innovative technology.
Other news from the department business & finance
